BIOGEN for BIOGEN
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the Trans-Pacific Partnership (TPP) trade agreement.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADAM GLUCK | Staff, Senate HELP Committee |
| KATHLEEN TREGONING | Staff, House Ways and Means Committee |
Taxation/Internal Revenue Code TAX
Support domestic and international corporate tax policies which protect and incentivize US-based research and manufacturing jobs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADAM GLUCK | Staff, Senate HELP Committee |
| KATHLEEN TREGONING | Staff, House Ways and Means Committee |
Health Issues HCR
1) Opposition to proposals to weaken incentives included in the biosimilars law for innovation and second generation therapies. 2) Support for appropriate guidance, comment period, and implementation timelines as required by PL 111-148 Section 6002. 3) Oppose efforts to expand importation of prescription drugs without adequate safety standards and patient protections.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADAM GLUCK | Staff, Senate HELP Committe |
| KATHLEEN TREGONING | Staff, House Ways and Means Committee |
Medicare/Medicaid MMM
Opposition to changes to Medicare Parts D and B reimbursement systems which could have adverse impact on patient access and US-based jobs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADAM GLUCK | Staff, Senate HELP Committee |
| KATHLEEN TREGONING | Staff, House Ways and Means Committee |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.